tumour markers
TRANSCRIPT
![Page 1: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/1.jpg)
TUMOR MARKERS
Dr. Asifa Iqbal
Oral And Maxillofacial Surgery ,KEMU Mayo Hospital,Lahore.
![Page 2: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/2.jpg)
Contents• What are tumor markers?• History• Ideal tumor markers• Clinical application• How to detect tumor markers • Broad classification• Specific classes of tumor markers• Specific tumor markers implicated in head & neck neoplasia• Drawbacks• New frontiers• Conclusion
![Page 3: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/3.jpg)
Tumor Markers?• Biological substances synthesized and released by
cancer cells themselves or
• Produced by the host in response to the presence of tumor
• Most tumor markers are proteins
• Detected in a solid tumor, in circulating tumor cells in blood, serum, lymph nodes, bone marrow or in other body fluids (urine, stool, ascites)
![Page 4: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/4.jpg)
Brief history of Tumor Markers
![Page 5: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/5.jpg)
Ideal Tumor Marker
• Be specific to the tumor.• Level should change in response to tumor size.• An abnormal level should be obtained in the presence of
micro metastases.• Levels in healthy individuals should be lower in
concentrations than those found in cancer patients.• Predict recurrences before they are clinically detectable.• Test should be cost effective.
![Page 6: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/6.jpg)
Ideal Tumor Marker????
![Page 7: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/7.jpg)
Clinical Application
• Screening To identify early cancer risk
• Diagnosis To corroborate the diagnosis
• Staging To assess & stratify the risk
• Prognosis To predict the outcome
• Localization To locate the primary
• Therapy To target the therapy
• Surveillance To detect recurrence in FU
• Monitoring To evaluate response to Rx.
![Page 8: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/8.jpg)
How to Detect Tumor Markers?
• ELISA • Immuno-histochemistry (IHC)• Polymerase chain reaction (PCR)• Fluorescence in situ hybridization (FISH)• Cluster Kits ( All-in-One Kit)
– Detects profiles– Patterns– Prototypes– Constellations
![Page 9: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/9.jpg)
Tumor MarkersAntigens
Hormones
Enzymes
Tissue Specific
TUMOR
![Page 10: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/10.jpg)
![Page 11: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/11.jpg)
![Page 12: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/12.jpg)
![Page 13: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/13.jpg)
![Page 14: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/14.jpg)
![Page 15: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/15.jpg)
DIAGNOSIS• FNAC (CYTOPATHOLOGY)
• FROZEN SECTIONS
• INCISIONAL BIOPSY FOLLOWED BY EXCISION
• LIGHT MICROSCOPY– H/E
![Page 16: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/16.jpg)
DIAGNOSIS, CONT• ELECTRON MICROSCOPY
• IMMUNOHISTOCHEMISTRY
• ENZYME HISTOCHEMISTRY– ALK. PHOSPHATASE IN OSTEOSARCOMA AND VAS. ENDOTHELIAL
TUMORS– ACID PHOS. IN GIANT CELL TUMOR AND HISTIOCYTIC TUMORS
• CYTOGENETICS AND MOLECULAR METHODS
![Page 17: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/17.jpg)
MORPHOLOGY OF CELLS
• SPINDLE CELL
• EXAMPLES– FIBROUS TUMORS – FIBROUS HISTIOCYTOMA – SMOOTH MUSCLE – SCHWANNOMA– NUROFIBROMA
![Page 18: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/18.jpg)
• SMALL ROUND CELL– SIZE OF A LYMPHOCYTE – WITH LITTLE CYTOPLASM
• EXAMPLES– RHABDOMYOSARCOMA – PRIMITIVE NEUROECTODERMAL TUMOR (PNET)
![Page 19: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/19.jpg)
• EPITHELIOD CELL– POLYHEDRAL – WITH CENTRAL NUCLEUS – ABUNDANT CYTOPLASM
• EXAMPLES– SMOOTH MUSCLE – ENDOTHELIAL, – SCHWANN CELL – EPITHELIOD SARCOMA
![Page 20: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/20.jpg)
ARCHITHECTURAL PATTERNS• FASCICLES OF EOSINOPHILIC SPINDLE CELLS INTERSECTING AT
RIGHT ANGLES– SMOOTH MUSCLE
• STORIFORM -SHORT FASCICLES OF SPINDLE CELLS RADIATING FROM A CENTRAL POINT,LIKE SPOKES OF A WHEEL.– FIBROHISTOCYTIC TUMORS
• NUCLEI ARRANGED IN COLUMNS -PALISADING– SCHWANN CELL
• HERRING BONE– FIBROSARCOMA
• MIXTURE OF SPINDLE CELL AND EPITHELIOD CELLS– SYNOVIAL SARCOMA
![Page 21: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/21.jpg)
IMMUNO-HISTOCHEMISTRY
• CYTOKERATIN,– EPITHELIAL CELLS– SARCOMATOID CARCINOMA – SYNOVIAL SARCOMA– EPITHELIOD SARCOMA– MESOTHELIOMAS– CHONDROSARCOMA
![Page 22: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/22.jpg)
• VIMENTIN– GENERAL MARKER OF CONNECTIVE TISSUE
• DESMIN– SMOOTH MUSCLE AND SKELETAL MUSCLE
• CHROMOGRANIN, SYNAPTOPHYSIN– NEUROBLASTOMA– PNET– PARAGANGLIOMA
![Page 23: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/23.jpg)
• EMA (Epithelial membrane antigen)– SARCOMATOID CARCINOMA – SYNOVIAL SARCOMA– MPNST– LEIOMYOSARCOMA– MESENCHYMAL TUMOR– EPITHELIOD SARCOMA– CHONDROSARCOMA
![Page 24: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/24.jpg)
• S100 PROTEIN– NERVOUS TUMORS– MELANOCYTIC TUMORS– PNET– LIPOSARCOMA– CHONDROSARCOMAS
![Page 25: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/25.jpg)
• DESMIN,– MUSCLE TUMORS – MYOFIBROBLASTIC LESIONS– SOME NEURAL TUMORS
• SMOOTH MUSCLE ACTIN – MUSCLE TUMORS – MYOFIBROBLASTIC LESIONS
![Page 26: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/26.jpg)
• CD34– VASCULAR TUMORS– SOLITARY FIBROUS TUMOR– FIBROHISTIOCYTIC TUMORS– SPINDLE CELL/ PLEOMORPHIC LIPOMAS– SOME NERVOUS TUMORS– EPITHELIOID SARCOMA
![Page 27: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/27.jpg)
• CD99– PNET– SYNOVIAL SARCOMA– EWING`S SARCOMA– LYMPHOBLASTIC LYMPHOMA– ALVEOLAR RHABDOMYOSARCOMA
![Page 28: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/28.jpg)
• SMOOTH MUSCLE ACTIN :– SMOOTH MUSCLE AND MYOFIBROBLASTS
• HHV8– KAPOSI SARCOMA
• CD31– NORMAL AND MALIGNANT ENDOTHELIAL CELLS
![Page 29: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/29.jpg)
• ANTICHYMOTRYPSIN/ANTI TRYPSIN– FIBROHISTIOCYTIC MARKER– HISTIOCYTIC LYMPHOMA– OSTIOSARCOMA
• MYOGLOBIN/MYOD-1– IMMATURE SKELETAL MUSCLE FIBERS
• NEURONE SPECIFIC ENOLASE(NSE)– NEURAL MARKER
![Page 30: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/30.jpg)
RHABDOMYOSARCOMA
• DESMIN• MYOGLOBIN• SK.MUSCLE MYOSIN• SK.MUSCLE ACTIN• CREATINE KINASE-M
![Page 31: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/31.jpg)
LEIOMYOSARCOMA
• SMOOTH MUSCLE ACTIN• DESMIN• MYOSIN
![Page 32: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/32.jpg)
NEURAL MARKERS
• S-100• NEUROFILAMENT• NSE• SYNAPTOPHYSIN• CHROMOGRANIN• CD 57• LEU-7• CD 99
![Page 33: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/33.jpg)
VASCULAR SARCOMAS• CD 31 +• CD 34 +• FACTOR 8 +• FLI 1 +• HHV 8 +/ -• CYTOKERATIN +/ -• EMA +/ -• C- KIT +/-• UEA 1
![Page 34: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/34.jpg)
Immunohistochemistry of GIST• CD117
– 95%• CD34
– 60- 70%• H- caldesmon
– 80%• SMA
– 15- 60%• S100 protein
– 5- 10%
![Page 35: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/35.jpg)
How to proceed
![Page 36: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/36.jpg)
PLAN• CYTOKERATIN +VE AND VIMENTIN –VE
– EPITHELIAL TUMORS
• CYTOKERATIN + VE AND VIMENTIN+VE• SYNOVIAL SARCOMA• EPITHELIOD SARCOMA• MESOTHELIOMA
• CYTOKERATIN – VE AND VIMENTIN -VE• NEURONE SPECIFIC ENOLASE(NSE) +
• GANGLIO-NEUROBLASTOMA
![Page 37: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/37.jpg)
CYTOKERATIN -VE AND VIMENTIN +VE
• DESMIN +– MYOGLOBIN+– SK.MUS.MYOSIN +– SK.MUS. ACTIN +
• RHABDOMYOSARCOMA
– SMOOTH MUSCLE MYOSIN +• LEIOMYOMA
![Page 38: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/38.jpg)
CYTOKERATIN - AND VIMENTIN +
• FACTOR VIII RELATED ANTIGEN +/ULEX EUROPEUS AGGULTININS +– VASCULAR TUMORS
• S100 +– NERVE TUMORS – LIPOSARCOMA– MELANOMA– GRANULAR CELL TUMOR
![Page 39: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/39.jpg)
CYTOKERATIN - AND VIMENTIN +
LC +• LYMPHOMA
– ALPHA 1 ANTI TRYPSIN (AAT)+– AACT +– LYSOZYME +– PEANUT AGG +
• HISTIOCYTIC LYMPHOMA
![Page 40: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/40.jpg)
CYTOKERATIN - AND VIMENTIN +
• ACT +– OSTEOSARCOMA– FIBRO HISTIOCYTIC TUMORS
• GFAP +• GLIOMAS• ASTEROCYTOMA
![Page 41: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/41.jpg)
![Page 42: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/42.jpg)
![Page 43: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/43.jpg)
Specific tumor markers implicated in oral neoplasms
• Alpha-1-Antichymotrypsin (1-ACT) & Factor XIIIa antibodies
• BCL-2• Beta 2-Microglobulin• CD44, CD80, CD105 • Cytokeratins• Cathepsin-D• CEA, CA19-9, CA125
• Carbohydrate associated antigens
• Calretinin• C-erb2• Cyclin, MIB• Growth factors• P-53
![Page 44: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/44.jpg)
![Page 45: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/45.jpg)
![Page 46: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/46.jpg)
Keratin and proliferation staining in the oral epithelium mice. Oral epithelium (lips) were immunostained for cytokeratin 13 (A–D), cytokeratin 6 (E–H), Ki-67 (I–L)
![Page 47: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/47.jpg)
![Page 48: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/48.jpg)
![Page 49: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/49.jpg)
![Page 50: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/50.jpg)
Figure 1: (a) H and E-stained section of a case of Burkitt lymphoma (note typical morphology with starry sky appearance); (b) a higher magnification of the same as in (a); (c) Bcl2 immunostaining on a case of BL (note focal weak cytoplasmic staining); and (d) Bcl2 immunostaining on a case of BL (note strong diffuse cytoplasmic staining)
Beta 2-Microglobulin:
![Page 51: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/51.jpg)
Tumor Markers - Drawbacks
• Cancer heterogeneity
• Lack of Specificity – false positives
• Lack of Sensitivity - false negatives
• Benign diseases - positive CA 125 or CEA
• Smokers have raised CEA
• Normal persons also have small amounts
• Higher levels only with large tumor volume
• Some cancers never have higher levels
![Page 52: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/52.jpg)
New Frontiers• Genomics: Gene structure.• Proteonomics: Protein structure.• Pharmacogenomics: Gene-based drugs structuring
and delivery.• G-scan: Human genome mapping.• New treatment modalities.• Individualised treatment modalities.• Early detection of malignant change.• Greater sensitivity and specificity.• Better monitoring and follow-up care.
![Page 53: Tumour markers](https://reader035.vdocuments.net/reader035/viewer/2022081422/58a1a7441a28abe6468b58d5/html5/thumbnails/53.jpg)
Conclusion• Tumor markers can’t be primary modalities for the
diagnosis of cancer. • Main utility in clinical medicine is a laboratory test to
support the diagnosis. • With the evolving understanding of genetics and
molecular basis of human malignancies, there has been much interest in determining whether specific molecular changes in different premalignant & malignant tumors might guide treatment decisions.